The Weekly Litigation News Digest is now live. Subscribe now
Antitumoral Combination Comprising Cabazitaxel And Cisplatin - EP2678011
The patent EP2678011 was granted to Aventis Pharma on Jun 26, 2019. The application was originally filed on Feb 24, 2012 under application number EP12706546A. The patent is currently recorded with a legal status of "Revoked".
EP2678011
- Application Number
- EP12706546A
- Filing Date
- Feb 24, 2012
- Status
- Revoked
- Nov 13, 2020
- Publication Date
- Jun 26, 2019
- External Links
- Slate, Register, Google Patents
Patent Summary
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (6) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents